Pharmacist warning to Mounjaro and Wegovy users over 'reminder' to women

An important reminder has been issued to women taking weight loss injections, with advice they may not have considered beforehand 12:03, 17 Nov 2026 Updated 12:04, 17 Nov 2026 Women taking a popular weight-loss injection have been urged to pay attention to advice that could have serious implications for anyone hoping to start a family . The warning comes as health officials remind patients that some medicines used to manage weight and diabetes are not suitable at certain stages of pregnancy planning. ‌ ‌ Northern Ireland’s Department of Health published the reminder after the Medicines and Healthcare products Regulatory Agency (MHRA) issued guidance on contraception and GLP-1 medicines. The advice covers several treatments, including Mounjaro, Wegovy, Ozempic, Saxenda and Victoza, and says they should not be used during pregnancy, while trying to conceive or while breastfeeding. ‌ Professor Cathy Harrison, Northern Ireland’s Chief Pharmaceutical Officer, said: "With use of weight loss medication on the rise in Northern Ireland and across the UK, it is timely that MHRA have issued this reminder to women who use these medications. ‌ "The reminder is clear; do not take GLP-1 medicines if you are pregnant, trying to get pregnant or breastfeeding. If you get pregnant while using them, you should speak to your healthcare professional and stop the medicine as soon as possible. "All patients, on any form of medication, should read the patient information leaflet, or speak with a healthcare professional as part of the prescribing process." ‌ Ensure our latest Health headlines always appear at the top of your Google Search by making us a Preferred Source. Click here to activate or add us as Preferred Source in your Google search settings Professor Harrison is a qualified pharmacist and has served as Northern Ireland’s Chief Pharmaceutical Officer since 2019, acting as the senior professional adviser on medicines and pharmacy matters. She was also made an Honorary Professor of Practice at Queen’s University Belfast in recognition of her contribution to pharmacy leadership and practice. ‌ The MHRA says there is not enough safety information to establish whether taking these medicines during pregnancy could harm an unborn baby. Its guidance says women taking Mounjaro, whose active ingredient is tirzepatide, should stop it at least one month before trying to become pregnant. ‌ There is also a specific warning for women who take the contraceptive pill alongside Mounjaro. The MHRA advises using an additional barrier method, such as condoms, for four weeks after starting treatment and for four weeks after every dose increase, or discussing a non-oral contraceptive option with a healthcare professional. NHS guidance also says tirzepatide should not be used during pregnancy because there is not enough information to confirm it is safe for the baby. Anyone who thinks they may be pregnant while taking it should contact their doctor or prescriber straight away rather than making decisions about their treatment without medical advice. Article continues below The MHRA says GLP-1 medicines should only be obtained with a prescription following a consultation with a healthcare professional. Patients are also urged to read the information leaflet supplied with their medicine and speak to their prescriber or pharmacist if they have questions about contraception, pregnancy or breastfeeding.